Compare SLGL & CHMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLGL | CHMG |
|---|---|---|
| Founded | 1997 | 1833 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.1M | 257.8M |
| IPO Year | 2016 | 1995 |
| Metric | SLGL | CHMG |
|---|---|---|
| Price | $69.80 | $55.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $110.00 | $57.00 |
| AVG Volume (30 Days) | ★ 17.5K | 3.2K |
| Earning Date | 03-19-2026 | 04-17-2026 |
| Dividend Yield | N/A | ★ 2.46% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.14 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $37.32 |
| Revenue Next Year | $223.84 | $9.13 |
| P/E Ratio | ★ N/A | $17.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $40.71 |
| 52 Week High | $97.97 | $65.50 |
| Indicator | SLGL | CHMG |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 54.82 |
| Support Level | $66.47 | $52.75 |
| Resistance Level | $71.43 | $57.08 |
| Average True Range (ATR) | 10.59 | 1.54 |
| MACD | -1.55 | 0.43 |
| Stochastic Oscillator | 19.72 | 87.59 |
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.